The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treating Lupus: Strategies, Treat to Target & Biologics

Treating Lupus: Strategies, Treat to Target & Biologics

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Skin manifestations of SLE.

Skin manifestations of SLE.
korn ratchaneekorn / shutterstock.com

CHICAGO—David A. Isenberg, MD, academic director of rheumatology, University College London, presented the ACR Systemic Lupus Erythematosus (SLE) State-of-the-Art Symposium at the 2018 ACR/ARHP Annual Meeting.

You Might Also Like
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
  • SLE Remission: The Treat-to-Target Approach
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
Explore This Issue
March 2019
Also By This Author
  • How to Leverage Patient-Reported Outcomes to Improve Care for SLE Patients

Dr. Isenberg began by noting lupus is now widely covered in the news, but singer Selena Gomez has probably done the most to increase awareness of the disease; her 2017 kidney transplant Instagram received more than 10 million likes. He encouraged rheumatologists to match this awareness and “up our game” with clinical assessment and understanding the totality of the effects of lupus on the patient.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Early recognition and treatment of SLE is important, Dr. Isenberg emphasized. Physicians should also be aware that damage from lupus implies permanent change, and lupus presents differently in different age groups. Although blood tests results reveal immunological changes in all patients, younger patients tend to have lower levels of C3. Younger patients are also more likely to have alopecia.

Treatment Strategies

Dr. Isenberg described SLE treatment strategies, explaining patients who have mild disease with fatigue and only malar rash should be treated with a single shot of steroids, with the possible addition of hydroxychloroquine (HCQ) and topical steroids. These patients can continue on a moderate dose of steroids and HCQ. Recent research suggests the use of glucocorticoids is more tightly associated with the treatment center than with patient symptoms or patient outcomes, meaning it may be possible to maintain patients without glucocorticoids.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

However, patients with moderate disease will likely require steroids and a maintenance dose of prednisone, Dr. Isenberg noted. These patients tend to present with fever and a larger rash. Although they may have renal involvement, it is not severe. In contrast, patients with severe disease tend to have large rashes, as well as severe pleurisy and/or pericarditis. These patients require more medications and are more likely to require steroids and immunosuppressive drugs for an extended period. Antimalarial agents, such as HCQ, adjunctive therapies and immunomodulation should all be considered as treatment options. Patients with lupus nephritis should be treated with immunosuppression for at least three years.

“Clearly, one has to see lupus patients regularly,” emphasized Dr. Isenberg, because it is vital to monitor drugs used in therapy closely. Regular visits should include serological tests, because an increase in double stranded DNA antibody is associated with an increased risk of renal disease. Regular management should also include  awareness of the increased risk for infection, cancer, vascular disease and osteoporosis; previously the major concern for patients with SLE was kidney failure.

Moreover, Dr. Isenberg pointed out the importance for healthcare providers to recognize concomitant damage may not necessarily be the result of disease activity. Shortness of breath, for example, could be due to pleuritis or pulmonary fibrosis. For each symptom, it is critical to question whether the symptom reflects disease activity or damage.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: 2018 ACR/ARHP Annual Meeting, abatacept, belimumab, Treat-to-TargetIssue: March 2019

You Might Also Like:
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
  • SLE Remission: The Treat-to-Target Approach
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)